IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer

Connie Bitelman, Rive Sarfstein, Menahem Sarig, Zohar Attias-Geva, Ami Fishman, Haim Werner, Ilan Bruchim

Research output: Contribution to journalArticlepeer-review

Abstract

This study evaluated the potential ability of MK-0646 to inhibit IGF1-mediated biological actions and cell signaling events in Type 1 and Type 2 endometrial cancer. We found that MK-0646 treatment significantly decreased IGF1R expression. In addition, pretreatment with MK-0646 decreased the IGF1-induced phosphorylation of IGF1R, AKT and ERK. Apoptosis analyses showed that MK-0646 abolished the anti-apoptotic effect of IGF1. Furthermore, MK-0646 treatment abolished the IGF1-stimulatory effect on proliferation and enhanced the cytotoxic effect of cisplatin. These findings indicate that specific inhibition of IGF1R could be a useful therapeutic approach for Type 1 and Type 2 endometrial cancer.

Original languageEnglish
Pages (from-to)153-159
Number of pages7
JournalCancer Letters
Volume335
Issue number1
DOIs
StatePublished - 10 Jul 2013

Keywords

  • Endometrial cancer
  • IGF1
  • IGF1 receptor
  • MK-0646
  • Uterine serous carcinoma

Fingerprint

Dive into the research topics of 'IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer'. Together they form a unique fingerprint.

Cite this